β-Thalassemia intermedia: A bird'S-eye view

dc.contributor.authorHaddad, Anthony G.
dc.contributor.authorTyan, Paul I.
dc.contributor.authorRadwan, Amr H.
dc.contributor.authorMallat, Naji S.
dc.contributor.authorTaher, Ali T.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentAnatomy, Cell Biology, and Physiological Sciences
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:45:04Z
dc.date.available2025-01-24T11:45:04Z
dc.date.issued2014
dc.description.abstractBeta-thalassemia is due to a defect in the synthesis of the beta-globin chains, leading to alpha/beta imbalance, ineffective erythropoiesis, and chronic anemia. The spectrum of thalassemias is wide, with one end comprising thalassemia minor, which consists of a mild hypochromic microcytic anemia with no obvious clinical manifestations, while on the other end is thalassemia major, characterized by patients who present in their first years of life with profound anemia and regular transfusion requirements for survival. Along the spectrum lies thalassemia intermedia, a term developed to describe patients with manifestations that are neither mild enough nor severe enough to be classified in the spectrum's extremes. Over the past decade, our understanding of β-thalassemia intermedia has increased tremendously with regards to molecular information as well as pathophysiology. It is now clear that β-thalassemia intermedia has a clinical presentation as well as complications associated with the disease that are different from those of β-thalassemia major. This review is designed to tackle issues related to β-thalassemia intermedia from the basic definition of the disease to paramedical issues, namely the quality of life in these patients. Genetics and pathophysiology are revisited, as well as the complications specific to this disease. These complications include effects on several organ systems, including the cardiovascular, hepatic, endocrine, renal, brain, and skeletal systems. Extramedullary hematopoiesis is also discussed in this article. Risk factors are highlighted and cutoffs are identified to minimize morbidities in β-thalassemia intermedia. Several treatment modalities are considered by shining a light on the pros and cons of each modality, as well as the role of special pharmacological agents in the progress of the disease and its morbidities. Finally, health-related quality of life is discussed in these patients with a direct comparison to the more severe β-thalassemia major.
dc.identifier.doihttps://doi.org/10.4274/Tjh.2014.0032
dc.identifier.urihttp://hdl.handle.net/10938/30526
dc.language.isoen
dc.publisherTurkish Society of Hematology
dc.sourceScopus
dc.subjectIneffective erythropoiesis
dc.subjectIron chelation
dc.subjectIron overload
dc.subjectThalassemia
dc.subjectThalassemia intermedia
dc.subjectAcetylsalicylic acid
dc.subjectAnticoagulant agent
dc.subjectBisphosphonic acid derivative
dc.subjectBosentan
dc.subjectCalcium
dc.subjectDeferasirox
dc.subjectDeferiprone
dc.subjectHydroxyurea
dc.subjectLow molecular weight heparin
dc.subjectPentoxifylline
dc.subjectSildenafil
dc.subjectZinc
dc.subjectAnemia
dc.subjectBone disease
dc.subjectBrain infarction
dc.subjectBrain pseudotumor
dc.subjectControlled clinical trial (topic)
dc.subjectEndocrine disease
dc.subjectExtramedullary hematopoiesis
dc.subjectFerritin blood level
dc.subjectFibrosis
dc.subjectHormonal therapy
dc.subjectHuman
dc.subjectLeg ulcer
dc.subjectLiver cancer
dc.subjectLiver cirrhosis
dc.subjectPulmonary hypertension
dc.subjectQuality of life
dc.subjectReview
dc.subjectRisk factor
dc.subjectSplenomegaly
dc.subjectThrombocytosis
dc.subjectThrombosis
dc.subjectTransfusion
dc.subjectVitamin supplementation
dc.titleβ-Thalassemia intermedia: A bird'S-eye view
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2014-10753.pdf
Size:
188.28 KB
Format:
Adobe Portable Document Format